OKYO Pharma Limited – Interim Results for the Six Months Ending 30 September 2022
[ad_1] LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused…
New Alzheimer’s test which allows earlier treatment could be used by NHS in three years
[ad_1] A brand new diagnostic check for Alzheimer’s that picks up the illness earlier might be utilized in hospitals inside…
After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer –
[ad_1] There’s been big progress in remedies for blood most cancers in recent times – however drawbacks of high-priced CAR-T…
Glasgow cancer scientists get £1.7m to crack new treatments
[ad_1] GLASGOW scientists are to obtain greater than £1.7 million from Cancer Research UK to analyze each the basis causes…
Experts appointed ‘to build Silicon Valleys of future’ in UK
[ad_1] Appointments Five trade specialists have been appointed by the federal government to speed up the event and deployment of…
pharma supplier, DTx, and non-profit hires from November 2022 –
[ad_1] Quite a few pharma-adjacent tech companies and non-profits introduced personnel information within the month of November. We’ve rounded up…
PrecisionLife Enters into a Multi Target R&D Collaboration Agreement with Ono Pharmaceutical
[ad_1] PrecisionLife OXFORD, United Kingdom, Dec. 14, 2022 (GLOBE NEWSWIRE) — PrecisionLife Limited (“PrecisionLife”), a world techbio firm producing the…
Ellipses Pharma Presents Preliminary Data From the First in Human Phase-1/2 Trial of EP0042, a Dual FLT-3 and Aurora Kinase Inhibitor, at ASH
[ad_1] News and analysis earlier than you hear about it on CNBC and others. Claim your 1-week free trial to…
Is the Scancell share price set to rocket in 2023?
[ad_1] Image supply: Getty Images So far, 2022 has been a rewarding yr for shareholders in Scancell (LSE: SCLP). The…
The mysterious UK Life Sciences Council –
[ad_1] Just because the life sciences {industry} is getting vocal about the way it’s faring, given the prospect of getting…